Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
about
Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infectionGuidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group.Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activitiesDifferences between generalists and specialists: knowledge, realism, or primum non nocere?Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods: branched DNA and Amplicor MonitorMechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variantsEffects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected personsSaquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administrationGenotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strainsDevelopment and validation of a composite programmatic assessment tool for HIV therapySafety and diagnostic value of brain biopsy in HIV patients: a case series and meta-analysis of 1209 patients.Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues.Determination of lamivudine/stavudine/efavirenz in human serum using liquid chromatography/electrospray tandem mass spectrometry with ionization polarity switch.Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study.Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170Mining the protein data bank to differentiate error from structural variation in clustered static structures: an examination of HIV protease.Long-term remission of HIV-associated thrombocytopenia parallels ongoing suppression of viral replicationComputational study of the resistance shown by the subtype B/HIV-1 protease to currently known inhibitors.Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.Significant interactions with new antiretrovirals and psychotropic drugs.Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysisRecent advances in antiviral therapy.Comparison of costs of strategies for measuring levels of human immunodeficiency virus type 1 RNA in plasma by using Amplicor and Ultra Direct assays.Delays in protease inhibitor use in clinical practicePharmacokinetic interaction between ritonavir and indinavir in healthy volunteersPatient-level moderators of the efficacy of peer support and pager reminder interventions to promote antiretroviral adherence.Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011.Tuberculosis: 9. Treatment.Immigrant women's health: Infectious diseases - Part 2.Recent advances. General medicine.Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohortAntimicrobial cycling: lessons learned from the aminoglycoside experience.Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population.HIV as a chronic disease: implications for long-term care at an AIDS-dedicated skilled nursing facilityA rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC)Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infectionIndinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infectionThe new antiretroviral "cocktails": is the stage set for HIV-positive women to benefit?
P2860
Q24247767-D69880C7-FBF3-41D0-923D-1C28C40FC9C8Q24534187-530C79A8-AEF2-44D1-92AD-9EBF5A432653Q24550608-AA0EB21B-FDD5-4F5D-9050-49E0C1D240C5Q24550613-1DEC9243-CEF1-441B-AB1C-7E3161112F5FQ27469406-23B6E6C1-263A-4F01-8F0B-8FFAB61B0D10Q28343606-98D78590-4914-429F-B99C-73889D4C2195Q28353070-44749400-86B6-4B4A-8AFF-75DC0F1FCF9FQ28354163-546D7A36-7DE4-4C0F-894E-87D7467CDA3AQ28369030-30AEB0BA-481A-4360-9519-AC640670E21FQ28379552-25E127A1-4EB6-4BCE-8D7D-E1D65C6E9E53Q28485260-4FDB5257-BAD3-4C5E-A6F5-AE094D62D553Q30251971-7603BAC6-99F1-465C-AA6B-5E2166B3ADCFQ30582507-CF703CA1-420E-4DBD-8BC0-01E6B14F07BCQ30847923-B08ADED2-1044-4807-842B-1A38EFF2E7D0Q33352323-93E95226-CE84-44ED-AFD9-E1010295F6E4Q33377920-868268EF-7B99-413B-9A10-E67FC521ACB3Q33454752-8CD41226-369D-46A4-B6BA-ED25AF4F8CFCQ33501309-352318FA-6DB4-41B1-A95A-F91F386F6F4FQ33563075-4BA55B0D-0DF6-4228-A8D3-3CB0653A233EQ33592278-0E71F8A6-03F3-4554-87F0-84A752FC9721Q33637697-54AEBFC0-2708-4436-A0E3-D5DE541E5C66Q33675233-EAF0C413-9ADB-4C32-BE65-EACAE3179C47Q33681664-7D5C1F60-4E3E-46A0-9D4A-7208DD785F9DQ33688291-D74B1ECE-0FA4-4D83-A0F3-CBCE4BD87B3AQ33694010-E6386291-9C5B-4343-95D7-0AA1D0C9386BQ33700538-9C6400AE-0C84-4031-B9C5-686138EA6B69Q33707680-69B605A1-BB24-42EA-9BCD-0D9DB011ACCAQ33713411-DA6EC8DD-561F-4F04-AC2F-6ECCD1B7E334Q33729210-7502BB90-6AD6-4A26-B480-0F661540EC16Q33729381-14542E82-3FCA-4BA0-9043-99C7144FDCDBQ33791941-BCECFC12-4BAB-4211-BC2A-D04E183D1345Q33813911-0782E6E5-22C0-4847-897E-94AEDF6790D4Q33827946-37EE9B03-2CB6-4EDD-AE59-8725898BF837Q33941936-4F024DEF-F248-4041-83BC-CD09F0BF529DQ33944372-9186C1AD-476A-46A4-8374-2DEAA3FBBAD3Q33976011-CF615F4E-86AF-4E67-A3D6-378D37F7B2F7Q33977187-A0F977E2-78B6-4EC8-BA93-17D69E3290FEQ33979006-36C249E5-BE8C-4504-9668-9F13814EF8E4Q33981606-E264732B-67D5-4C2A-816D-61AAF2C5BD42Q34027415-74DEA131-5DE1-4FA1-978E-67F84CEAB3C2
P2860
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Antiretroviral therapy for HIV ...... tional AIDS Society-USA panel.
@en
type
label
Antiretroviral therapy for HIV ...... tional AIDS Society-USA panel.
@en
prefLabel
Antiretroviral therapy for HIV ...... tional AIDS Society-USA panel.
@en
P2093
P1476
Antiretroviral therapy for HIV ...... tional AIDS Society-USA panel.
@en
P2093
C C Carpenter
D A Katzenstein
D D Richman
D M Jacobsen
J S Montaner
M A Fischl
M A Thompson
M S Hirsch
P A Volberding
P304
P356
10.1001/JAMA.1997.03540480062040
P407
P577
1997-06-01T00:00:00Z